Postmenopausal Osteopenia
Conditions
Keywords
postmenopausal osteoporosis, aerobic exercise, bone turnover markers
Brief summary
The aim of the study was to evaluate the effect of light-moderate aerobic exercise on BMD in postmenopausal osteopenic women using bone formation-resorption markers. Participants were randomized into two groups as aerobic exercise and control groups and followed for 12 weeks. At the beginning and at the 12th week, bone formation-resorption markers including procollagen type 1 N-terminal propeptide (P1NP), cross-linked C-telopeptide of type 1 collagen (CTX), osteocalcin, malondialdehyde, non-bone-specific total alkaline phosphatase, 25(OH)D3 and oxidative markers such as parathyroid hormone (PTH) were evaluated in serum and whether there was a difference between the 2 groups.
Detailed description
The aim of the study was to investigate the effects of light and moderate intensity aerobic exercise on bone mineral density (BMD) in postmenopausal osteopenic women using bone formation and resorption markers. In a prospective, randomized, controlled, single-blind clinical trial, women aged 45-65 years with BMD T scores between -1 and -2.5 measured by double X-ray absorptiometry (DXA) were included in the study after evaluation of exclusion criteria and the women were divided into 2 groups: aerobic exercise group and control group (exercise, n=25; control, n=25). The exercise group participated in a supervised aerobic exercise program consisting of walking on a treadmill for 30 minutes per day, 3 days per week, at an intensity of 40-60% of maximal heart rate for 4 weeks. Additionally, they were shown an exercise program at the initial assessment that included balance, posture, and endurance exercises using body weight and weights to be performed 3 days a week, with 3 sets of 10 repetitions. The control group did not participate in any exercise program.All patients were prescribed 2000 IU of vitamin D (cholecalciferol) and 1200 mg of calcium carbonate daily for 12 weeks. Serum levels of biomarkers of bone formation and resorption including procollagen type 1 N-terminal propeptide (P1NP), cross-linked C-telopeptide of type 1 collagen (CTX), osteocalcin, malondialdehyde, non-bone-specific total alkaline phosphatase, 25(OH)D3 and oxidative markers such as parathyroid hormone (PTH) were examined in all patients at baseline and 12-week follow-up. Nottingham Health Profile questionnaire (NHP), Visual analog scale (VAS), 6-minute walk test (6MWT), International Physical Activity Questionnaire (short form) (IPAQ), Berg Balance Scale (BBS), 30-second sit-to-stand test questionnaires (30s-CST) tests were performed at baseline and 12 weeks to evaluate the participants' quality of daily life, pain, walking speed, physical activity level and balance.
Interventions
OTHERaerobic exercise
The exercise group participated in a supervised aerobic exercise program consisting of walking on a treadmill for 30 minutes per day, 3 days per week, at an intensity of 40-60% of maximal heart rate for 4 weeks. Additionally, they were shown an exercise program at the initial assessment that included balance, posture, and endurance exercises using body weight and weights to be performed 3 days a week, with 3 sets of 10 repetitions. The control group did not participate in any exercise program.
OTHERcholecalciferol
Participants were prescribed 2000 IU of vitamin D (cholecalciferol) daily for 12 weeks.
OTHERcalcium carbonate
Participants were prescribed 1200 mg of calcium carbonate daily for 12 weeks.
Sponsors
Bursa Yuksek Ihtisas Training and Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Masking description
Patients who met the inclusion criteria were randomized into 2 groups with the investigator blinded.
Intervention model description
Patients who met the inclusion criteria were randomized into 2 groups with the investigator blinded. Participants in the exercise group were included in an aerobic exercise program, while patients in the control group were not included in any exercise program. All patients underwent serum marker assessment and clinical examination both at baseline and after 12 weeks of follow-up.
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Postmenopausal women from Türkiye aged 45-65 years, * Bone mineral density (BMD) T-scores between -1 and -2.5 ( measured by dual-energy X-ray absorptiometry)
Exclusion criteria
* Vertebral compression fracture, * A history of traumatic or nontraumatic fractures in the past year, * Thyroid hormone disorders, * Parathyroid hormone disorders, * Liver function disorders, * Kidney function disorders, * Chronic heart failure, * A history of malignancy, * A history of rheumatological diseases, * Corticosteroid use, * Immunosuppressive drug use, * Anticonvulsant and heparin use, * Antiresorptive or anabolic agent treatments use * Hormone replacement therapy use * Those who could not complete sessions due to mechanical pain exacerbated during aerobic exercise on a treadmill (such as knee and hip osteoarthritis, back pain, etc)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The serum levef of Procollagen type 1 N-terminal propeptide (P1NP) (ng/ml) | From enrollment to the end of treatment at 12 weeks | Bone turnover markers allow for the independent assessment of bone resorption and formation by measuring their concentrations in blood and urine. These markers provide early response evaluation posttreatment of osteoporosis compared to measuring BMD. The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend evaluating P1NP for bone formation activity and evaluating CTX-1 concentrations for bone resorption activity. In the study,the investigators chose walking exercise as an aerobic exercise that can be easily applied to people of all age groups and those with comorbidities. For these reasons, as the primary outcome of the study, the investigators aimed to measure the effects of aerobic exercise as a treatment method that can be recommended to the majority of patients, as bone turnover markers P1NP, CTX, OCN and total ALP respond quickly to treatment. |
| The serum levef of Cross-linked C-telopeptide of type I collagen (CTX) (ng/ml) | From enrollment to the end of treatment at 12 weeks | During bone resorption, components of bone tissue are catabolized by osteoclasts. The released components are released into the bone microenvironment and secreted into the bloodstream. Some of them are also excreted in the urine. The level of C-telopeptide type 1 collagen(CTX)(ng/ml) can be measured in serum from these products. . The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend evaluating CTX-1 concentrations for bone resorption activity. |
| The serum levef of Osteocalcin(OCN) (ng/ml) | From enrollment to the end of treatment at 12 weeks | During bone formation, osteoblasts fill the cavities with collagen-rich tissue and the molecules formed during their production are secreted into the blood. These products are; Type 1 procollagen N-terminal propeptide (P1NP), bone alkaline phosphatase, Osteocalcin, Type-1 procollagen C-terminal propeptide. These molecules also show bone formation activity. |
| The serum levef of nonbone-specific total alkaline phosphatase (ALP) (U/L) | From enrollment to the end of treatment at 12 weeks | During bone formation, osteoblasts fill the cavities with collagen-rich tissue and the molecules formed during their production are secreted into the blood. These products are; Type 1 procollagen N-terminal propeptide (P1NP), bone alkaline phosphatase, Osteocalcin, Type-1 procollagen C-terminal propeptide. These molecules also show bone formation activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| International Physical Activity Questionnaire (short form)(IPAQs) | From enrollment to the end of treatment at 12 weeks | The International Physical Activity Questionnaire (short form) (IPAQs) is used to assess daily physical activity levels. IPAQs consist of 7 questions that assess the time patients spent physically in the last 7 days. These questions assess physical activity in 2 categories: vigorous, moderate and low-level physical activity or weekly MET/minute. MET/minute indicates the amount of energy expended while performing physical activity. While IPAQs are calculated as weekly METs, 3.3 METs are calculated for a minute of low-level physical activity; 4 METs for moderate-level physical activities; 8 METs for a minute of vigorous physical activities. Expending 1500-3000 METs of energy in 1 week is considered vigorous physical activity; 600-1500 METs is considered moderate physical activity, and individuals with less than 600 METs are considered in the light physical activity group. The investigators aimed to assess participants' post-exercise physical activity levels with IPAQs. |
| Berg Balance Scale (BBS) | From enrollment to the end of treatment at 12 weeks | Berg Balance Scale (BBS) is a 14-question test used to evaluate the balance and fall risk of elderly individuals. Each item is scored between 0-4 according to the patient's level and speed of performing the desired movement. Patients were evaluated between 0-56 points in total. 0-20 points indicate balance disorder, 21-40 points indicate acceptable balance, and 41-56 points indicate good balance. The investigators aimed to evaluate the balance level of patients after exercise with BBS. |
| Serum level of Malondİaldehyde(MDA) (ng/ml) as a Oxidative stress marker | From enrollment to the end of treatment at 12 weeks | Oxidative stress is considered an important pathogenic factor of osteoporosis at the cellular and molecular level. It induces osteocyte apoptosis and altered levels of specific factors such as receptor activator κB ligand (RANKL), sclerostin and fibroblast growth factor 23, leading to impaired bone remodeling and increased bone resorption. Increased osteoclastic activity occurring in osteoporosis results in increased production of ROS in the form of superoxide. Lipid peroxidation is one of the most deleterious effects of ROS, and the end product of lipid peroxidation, malondialdehyde (MDA), also serves as a measure of osteoclastic activity. For this reason, increased levels of MDA as a marker of oxidative stress can be detected in individuals with osteoporosis. In the study, the investigators aimed to observe the changes in the serum level of malondialdehyde, one of the oxidative stress markers, with aerobic exercise. |
| The serum levef of Parathyroid hormone (PTH)(pg/ml) | From enrollment to the end of treatment at 12 weeks | Parathyroid hormone (PTH) plays an important role in regulating calcium and phosphorus metabolism in the body by acting directly on human bones and kidneys and indirectly on the human intestine. In doing so, it affects both bone formation and bone resorption. |
| 30-second sit-to-stand test questionnaires(30s-CST) | From enrollment to the end of treatment at 12 weeks | 30-second sit-to-stand test questionnaires(30s-CST) evaluates the patient's lower extremity strength and dynamic balance during activity. The investigators aimed to evaluate the lower extremity strength and dynamic balance of the patients after exercise. |
| Nottingham Health Profile questionnaire (NHP) | From enrollment to the end of treatment at 12 weeks | Nottingham Health Profile questionnaire (NHP) was used to measure patients' quality of life. NHP consists of section 1 consisting of 38 detailed questions about health and section 2 consisting of 7 questions about the areas of daily life most affected by health. Section 1 questions 6 areas related to health in detail: pain, emotional reactions, sleep, social isolation, physical activity, energy. Each subsection is evaluated between 0-100 points. Section 2 consists of seven statements about the areas of daily life most affected by health: work, daily chores at home, social life, personal relationships, sexual life, hobbies-interests, and holidays. Here, patients are evaluated between 0-7 points, with 1 point for each statement. Patients were evaluated between 0-600 points for section 1, 0-7 points for section 2, and 0-607 points as the NHP Total score. |
| Visual analog scale (VAS) | From enrollment to the end of treatment at 12 weeks | Visual analog scale (VAS) was used to evaluate and monitor the level of pain felt by the patients. The investigators aimed to evaluate the pain level of patients after exercise with VAS.Patients were asked to mark on a 100 mm long line divided into 10 units and numbered from 0 to 10; 0 (zero) I have no pain, 10 the most severe pain I have ever felt. The number marked was recorded as the VAS pain score. |
| 6-minute walk test (6MWT) | From enrollment to the end of treatment at 12 weeks | 6-minute walk test (6MWT) was used to assess the functional capacity of patients and is a valid and reliable test as an indicator of physical endurance in elderly individuals. The investigators aimed to evaluate the functional capacity of patients after exercise with 6MWT. |
Countries
Turkey (Türkiye)
Outcome results
None listed